Novartis takes on Regeneron with AMD drug that needs fewer doses than Eylea
admin 20th June 2017 Uncategorised 0Last year, U.S. sales of Regeneron’s drug to treat age-related macular degeneration (AMD) came in at $3.3 billion—68% of the company’s total revenues—so it’s no wonder investors have been expressing some concerns about potential rivals moving through the pipeline. Among those hoping to cut into Eylea’s market is Novartis, which is in phase 3 testing with its AMD candidate, RTH258.
More: Novartis takes on Regeneron with AMD drug that needs fewer doses than Eylea
Source: fierce